Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
Glycogen Storage Disease Type IAThe main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.
null
Conditions de participation
-
Sexe:
ALL -
Âges admissibles:
2 and up
Critères de participation
Inclusion Criteria:
* Patient who had:
* DTX401 (full or partial dose) administered in a parent clinical study (Group 1) or
* Prescribed DTX401(full or partial dose) administered in a post-marketing setting (Group 2)
* Patient is willing and able to provide informed consent after the nature of the study has been explained, and prior to any research-related assessments or procedures. If a minor or an adult with cognitive limitations, the patient is willing and able (if possible) to provide assent and have a legally authorized representative provide informed consent after the nature of the study has been explained, and prior to any research-related assessments or procedures.
Exclusion Criteria:
* Presence of any condition that would interfere with study participation, interpretation of results or affect patient's safety in the opinion of the Investigator
Lieu de l'étude
McGill University Health Center
McGill University Health CenterMontréal, Quebec
Canada
Contactez l'équipe d'étude
- Étude parrainée par
- Ultragenyx Pharmaceutical Inc
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT06636383